Altimmune, Inc. (ALT) insider trading

By person

30 insiders · 122 transactions

Insider

Role

Bought

Sold

Net

Holding

Worth

Change

Venrock Healthcare Capital Partners III, L.P. entity

10% owner

$22.71M (7)

—

+$22.71M

3,500,000

$10.33M

+106.3%

Prescott Group Capital Management, L.l.c. entity

10% owner

—

$4.41M (3)

−$4.41M

6,626,403

$19.55M

−17.0%

M Scot Roberts

Chief Scientific Officer

$1.98K (1)

$959.77K (4) scheduled

−$957.78K

113,714

$335.46K

—

Velocity Pharmaceutical Holdings LLC entity

10% owner

—

$957.10K (2)

−$957.10K

1,687,250

$4.98M

−10.6%

Derace L Schaffer

Director

$943.38K (25)

—

+$943.38K

601,846

$1.78M

+521.9%

Vipin K Garg

Director

$42.00K (1)

$626.21K (2)

−$584.21K

424,519

$1.25M

—

Wayne Pisano

Director

$29.59K (2)

$402.75K (2) scheduled

−$373.16K

13,498

$39.82K

—

Matthew Scott Harris

Chief Medical Officer

$42.20K (1)

$265.83K (2) scheduled

−$223.63K

16,087

$47.46K

—

Jerome Benedict Durso

President and CEO

$213.71K (4)

—

+$213.71K

62,500

$184.38K

—

Diane Jorkasky

Director

$2.00K (1)

$206.94K (1) scheduled

−$204.94K

527

$1.55K

—

Philip Hodges

Director

—

$143.09K (3)

−$143.09K

26,579

$78.41K

—

Gregory L Weaver

Chief Financial Officer

$101.20K (3)

—

+$101.20K

49,927

$147.28K

—

Klaus Schafer

Director

$23.98K (1)

$100.59K (1)

−$76.61K

9,179

$27.08K

—

John Gill

Director

$86.94K (3)

$141.14K (2)

−$54.19K

21,700

$64.02K

—

Richard I Eisenstadt

Chief Financial Officer

$43.14K (1)

—

+$43.14K

45,012

$132.79K

—

David Drutz

Director

$74.79K (6)

$110.55K (2) scheduled

−$35.76K

76,008

$224.22K

—

Mitchel Sayare

Director

$9.96K (1)

—

+$9.96K

59,013

$174.09K

—

Catherine A. Sohn

Director

$7.90K (2)

—

+$7.90K

1,500

$4.43K

—

William Enright

President and CEO

$659.88 (1)

—

+$659.88

365,839

$1.08M

+1,306,468%

Novartis Bioventures Ltd entity

10% owner

—

8,345,145

$24.62M

+346.9%

Eric I Richman

Director

—

908,055

$2.68M

+114.0%

Peter Steven St

Director

—

205,004

$604.76K

+51.9%

Jeffrey W. Runge

Director

—

197,700

$583.22K

+25.4%

Philip Macneill

VP, CFO, Treasurer, Secretary

—

126,346

$372.72K

+21.9%

Truffle Capital S.A.S. entity

10% owner

—

76,700

$226.27K

—

Raymond M Jordt

Chief Business Officer

—

70,107

$206.82K

+778,867%

Christophe Arbet-Engels

Chief Medical Officer

—

24,821

$73.22K

—

William Michael Brown

Chief Financial Officer

—

17,721

$52.28K

—

Linda M Richardson

Chief Commercial Officer

—

17,174

$50.66K

—

Andrew Shutterly

Acting Chief Financial Officer

—

11,372

$33.55K

+12.4%

No percentages here. This company's share count has moved by a factor of 2.5 over the window, from 77,013,658 to 194,517,701 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Altimmune, Inc.

What the insiders did Net buying

By person